Summary Although no game-changing studies in bladder cancer were presented this year at ASCO, we saw a series of interesting data including follow-up updates, exploratory analyses and promising results phase I/II trials. An up-date analysis the JAVELIN 100 Bladder study indicated benefit avelumab maintenance treatment irrespective response to platin-based first-line administration second-line t...
